TY - JOUR
T1 - Dose-dependent effects of flumazenil on cognition, mood, and cardio-respiratory physiology in healthy volunteers
AU - Neave, Nick
AU - Reid, C.
AU - Scholey, Andrew
AU - Thompson, J.M.
AU - Moss, Mark
AU - Ayre, Gareth
AU - Wesnes, Keith
AU - Girdler, Nick
PY - 2000/12/23
Y1 - 2000/12/23
N2 - Objectives: To assess the possible effects of flumazenil on cognitive processing, physiology, and mood.
Design: A double-blind, placebo controlled, four-way cross-over study, using healthy volunteers.
Methods: On each of 4 separate visits, 16 participants received 0.5mg, 2.5mg, 5.0mg of flumazenil, or normal saline. They then performed a computerised test battery assessing cognitive function. Measures of pulse rate, arterial oxygen saturation and mean arterial pressure were also taken. Finally, participants completed visual analogue scales assessing their subjective mood state. Results: The majority of cognitive tasks showed dose-dependent declines in performance. Mean arterial pressure was significantly reduced, as was pulse rate. Subjective alertness showed a similar decline.
Conclusions: Flumazenil has been clinically described as an agent with few intrinsic properties, whose primary effect lies in its ability to reverse benzodiazepine-induced states. This study has shown that flumazenil does possess intrinsic activity which have a significant effect on cognition, cardiovascular physiology and mood. Clinicians need to be aware of these effects.
AB - Objectives: To assess the possible effects of flumazenil on cognitive processing, physiology, and mood.
Design: A double-blind, placebo controlled, four-way cross-over study, using healthy volunteers.
Methods: On each of 4 separate visits, 16 participants received 0.5mg, 2.5mg, 5.0mg of flumazenil, or normal saline. They then performed a computerised test battery assessing cognitive function. Measures of pulse rate, arterial oxygen saturation and mean arterial pressure were also taken. Finally, participants completed visual analogue scales assessing their subjective mood state. Results: The majority of cognitive tasks showed dose-dependent declines in performance. Mean arterial pressure was significantly reduced, as was pulse rate. Subjective alertness showed a similar decline.
Conclusions: Flumazenil has been clinically described as an agent with few intrinsic properties, whose primary effect lies in its ability to reverse benzodiazepine-induced states. This study has shown that flumazenil does possess intrinsic activity which have a significant effect on cognition, cardiovascular physiology and mood. Clinicians need to be aware of these effects.
U2 - 10.1038/sj.bdj.4800860
DO - 10.1038/sj.bdj.4800860
M3 - Article
SN - 0007-0610
VL - 189
SP - 668
EP - 674
JO - British Dental Journal
JF - British Dental Journal
IS - 12
ER -